[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 014″]
At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, President & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Medical Optics; and Ashley McEvoy, Company Group Chairman of Johnson & Johnson Vision Care shared how they balance external innovation with the acquisition of outside technologies to further the ophthalmic franchises.
Jeff was appointed to lead Alcon in May 2014. As the global leader in eye care, Alcon provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses – Surgical, Pharmaceutical, and Vision Care – offer one of the widest portfolios of eye care products in the world, with 2014 sales of USD 10.8 billion.
David E.I. Pyott
David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties.
Murthy V. Simhambhatla
Murthy V. Simhambhatla, PhD, is Sr. VP, Abbott Medical Optics, heading up the company’s global vision care business. Dr. Simhambhatla was appointed to this position in January 2013. Previously, he served as General Manager of the Ibis Biosciences unit of Abbott Diagnostics. Dr. Simhambhatla joined Abbott in 2006 through its acquisition of Guidant Corporation, as Divisional Vice President and General Manager for Drug Eluting Stents.
Ashley McEvoy serves as Company Group Chairman, Johnson & Johnson Vision Care and Johnson & Johnson Diabetes Solutions, two medically directed, consumer informed businesses within Johnson & Johnson’s global medical device segment.